Clario’s Precision Motion Opal Credited with Oxford Parkinson’s Discovery


Findings offer promising implications for neuroscience clinical trials and future treatments, company says.

Close up hands of senior elderly woman patient suffering from pakinson's desease symptom. Mental health and elderly care concept. Image Credit: Adobe Stock Images/ipopba

Image Credit: Adobe Stock Images/ipopba

Clario, a healthcare research technology company, revealed in a company press release that researchers at Oxford University have successfully developed a new understanding of motor symptom progression in Parkinson's Disease through the use of its Precision Motion Opal technology. Reportedly, a study that leveraged the company’s wearable sensors and machine learning enabled researchers with the ability to track the motor symptom progression in individuals with Parkinson's Disease (PD) better than the conventionally used clinical rating scales. Additionally, results found that the device discovered disease progression in a significantly shorter timeframe than the traditional method.

"We are honored to support Professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field," said Kristen Sowalsky, PhD, DC, VP of Medical & Scientific Affairs, Clario. "This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson's Disease progression more accurately and assess the efficacy of early therapeutic intervention. The potential impact of these findings for neuroscience clinical trials is outstanding."

Reference: Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease. PR Newswire. October 27, 2023. Accessed October 31, 2023.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.